Woman with safety glasses
Woman with safety glasses

Our Pipeline

An overview of the clinical studies on our own drug candidates and the most advanced clinical programs of our partners.

Our Pipeline

Latest Update: August 2024

MorphoSys' Clinical Programs

Compound / Brand name
Indication
NCT
Pelabresib
Target BET Inhibitor
Myelofibrosis (MANIFEST-2)
Myelofibrosis / Essential Thrombocythemia (MANIFEST)
Tulmimetostat
Target EZH1/EZH2 Dual Inhibitor
Advanced Solid Tumors / Hematologic Malignancies

Selection of our Partners’ Clinical Programs

Compound / Brand name
Partner
Program
Compound / Brand name
Ianalumab (VAY736)
Partner
Novartis
Program

Ianalumab is an antibody that targets B-cell activating factor receptor (BAFF-R), designed to block BAFF-R-mediated signaling and to deplete B-cells through antibody-dependent cellular cytotoxicity. It is being investigated in multiple Phase 3 studies, including for Sjögren’s disease, lupus nephritis, systemic lupus erythematosus, immune thrombocytopenia (first-line and second-line) and warm autoimmune hemolytic anemia, and a Phase 2/3 study for autoimmune hepatitis. 

Compound / Brand name
Abelacimab (MAA868)
Partner
Anthos Therapeutics
Program

Abelacimab is an antibody that selectively binds and blocks the activity of Factor XI and its active form Factor XIa, to protect against thromboembolic events. It is being investigated in a Phase 3 study in patients with atrial fibrillation (AF), and in two ongoing complementary Phase 3 studies in patients with cancer-associated thrombosis (CAT). A Phase 2 study in AF was stopped early due to an overwhelming benefit (reduction in bleeding). Abelacimab has been granted Fast Track designation by the U.S. Food and Drug Administration (FDA) in both the AF and CAT indications.

Compound / Brand name
Setrusumab (BPS804/UX143)
Partner
Mereo Biopharma and Ultragenyx
Program

Setrusumab is an antibody that inhibits sclerostin, a negative regulator of bone formation. It is being investigated in the Phase 3 portion of a pivotal Phase 2/3 clinical study and in a Phase 3 study, both for the treatment of osteogenesis imperfecta (OI). The studies are supported by positive Phase 2 data demonstrating that setrusumab significantly reduced fracture rates in patients with OI. Setrusumab has been granted Rare Pediatric Disease Designation by the FDA.

Compound / Brand name
Felzartamab
Partner
HIBIO-I-Mab
Program

Felzartamab is an antibody that targets CD38, a protein broadly expressed on malignant myeloma cells and antibody-producing plasmablasts and plasma cells. It is being investigated by HI-Bio in two renal autoimmune diseases, anti-PLA2R antibody-positive membranous nephropathy and immunoglobulin A nephropathy. These studies are supported by positive Phase 2 data and a recent FDA Breakthrough Therapy designation in primary membranous nephropathy. Felzartamab is also being investigated by TJ Biopharma (früher I-Mab Biopharma) in relapsed/refractory multiple myeloma.

Compound / Brand name
Bimagrumab
Partner
Lilly
Program

Bimagrumab is an antibody that binds activin type II A and B receptors to block activin and myostatin signaling, which can cause wasting in muscles and storage of fat in adipose tissue. It is currently being investigated in a Phase 2b study as a novel treatment for overweight and obesity, as both a monotherapy and in combination with semaglutide. 

Compound / Brand name
MOR210/TJ210/HIB210
Partner
HIBIO-I-Mab
Program

MOR210/TJ210/HIB210 is an antibody that targets C5aR1, the receptor of the complement factor C5a, a novel therapeutic target with potential in the fields of autoimmune diseases and immuno-oncology. It is being investigated by TJ Biopharma (früher I-Mab Biopharma) for the treatment of advanced solid tumors and by HI-Bio in a Phase 1 study in healthy volunteers.

MORPHOSYS’ CLINICAL PROGRAMS

Pelabresib

Pelabresib

Pelabresib is an investigational BET inhibitor being studied in myelofibrosis and other myeloid diseases.

Tulmimetostat

Tulmimetostat

Tulmimetostat is an investigational next-generation dual EZH2/EZH1 inhibitor being explored in solid tumors and lymphomas.